Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 2/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22304838 | 0.93 | PYCR1 (0.60) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL13232509 | 0.91 | PYCR1 (0.58) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL21268450 | 0.91 | ALDH1A1 (0.63) | PYCR1ALDH1A1NPC1KDM4ESMN1; SMN2 | |
| SCHEMBL3240150 | 0.89 | PYCR1 (0.56) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL3153174 | 0.89 | PYCR1 (0.56) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL171946 | 0.88 | PYCR1 (0.60) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| Hydrochloric Acid SCHEMBL27258921 | 0.86 | PYCR1 (0.58) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL3339451 | 0.86 | PYCR1 (0.58) | PYCR1TAAR1ALDH1A1NPC1AOC3 | |
| SCHEMBL13889677 | 0.84 | TAAR1 (0.61) | PYCR1TAAR1ALDH1A1AOC3KDM4E | |
| SCHEMBL15308539 | 0.84 | PYCR1 (0.56) | PYCR1TAAR1ALDH1A1AOC3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200044154-A1 | ORGANIC ELECTRONIC MATERIAL, INK COMPOSITION, ORGANIC ELECTRONIC ELEMENT, AND ORGANIC ELECTRONIC ELEMENT PRODUCTION METHOD | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| US-9573888-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-06-16 | — | — | US | disclosed |
| US-9296728-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2014-12-18 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-6953679-B2 | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040176324-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1319007-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024702-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371272-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | PYCR1 877/4885TAAR1 2693/4885ALDH1A1 266/4885 |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | SUCNR1, SHBG, FSHR | PYCR1 418/4885TAAR1 4135/4885ALDH1A1 1888/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | PYCR1 498/4885TAAR1 3757/4885ALDH1A1 3219/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | PYCR1 498/4885TAAR1 3757/4885ALDH1A1 3219/4885 |
| US-20160168083-A1 | THERAPEUTIC COMPOUNDS | HLA-DRB1, SLC10A1, NFATC1 | PYCR1 1031/4885TAAR1 2704/4885ALDH1A1 359/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | PYCR1 498/4885TAAR1 3757/4885ALDH1A1 3219/4885 |
| US-20040176324-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | PYCR1 498/4885TAAR1 3757/4885ALDH1A1 3219/4885 |
| US-20200044154-A1 | ORGANIC ELECTRONIC MATERIAL, INK COMPOSITION, ORGANIC ELECTRONIC ELEMENT, AND ORGANIC ELECTRONIC ELEMENT PRODUCTION METHOD | ARF1, SLC43A1, RIF1 | PYCR1 3503/4885TAAR1 2140/4885ALDH1A1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.